Should I buy or sell Halozyme Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HALO shares. View HALO analyst ratings or view top-rated stocks .

What is Halozyme Therapeutics' stock price target for 2024?

7 equities research analysts have issued 1 year price targets for Halozyme Therapeutics' stock. Their HALO share price targets range from $40.00 to $72.00. On average, they expect the company's stock price to reach $53.29 in the next twelve months. This suggests a possible upside of 38.9% from the stock's current price. View analysts price targets for HALO or view top-rated stocks among Wall Street analysts .

How have HALO shares performed in 2024?

Halozyme Therapeutics' stock was trading at $36.96 at the beginning of 2024. Since then, HALO shares have increased by 3.8% and is now trading at $38.36. View the best growth stocks for 2024 here .

When is Halozyme Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our HALO earnings forecast .

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued its earnings results on Tuesday, February, 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.77 by $0.02. The biopharmaceutical company earned $230.04 million during the quarter, compared to analysts' expectations of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a trailing twelve-month return on equity of 248.20%.

What ETFs hold Halozyme Therapeutics' stock?

ETFs with the largest weight of Halozyme Therapeutics (NASDAQ:HALO) stock in their portfolio include Future Fund Long/Short ETF (FFLS) , Future Fund Active ETF (FFND) , Invesco Biotechnology & Genome ETF (PBE) , Virtus LifeSci Biotech Products ETF (BBP) , BlackRock Future Innovators ETF (BFTR) , Goldman Sachs Future Health Care Equity ETF (GDOC) , SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU) .

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics updated its FY 2024 earnings guidance on Tuesday, February, 20th. The company provided EPS guidance of 3.550-3.900 for the period, compared to the consensus estimate of 3.510. The company issued revenue guidance of $915.0 million-$985.0 million, compared to the consensus revenue estimate of $961.1 million.

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com . Helen Torley has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include Xtrackers California Municipal Bond ETF (CA) , Endologix (ELGX) , BlackRock (BLK) , Chipotle Mexican Grill (CMG) , Micron Technology (MU) , Gilead Sciences (GILD) , Athabasca Oil (ATH) , NIC (EGOV) , Allergan (AGN) and AbbVie (ABBV) .

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (0.32%), Hodges Capital Management Inc. (0.25%), Los Angeles Capital Management LLC (0.10%), Brookstone Capital Management (0.05%), FCF Advisors LLC (0.02%) and Park Avenue Securities LLC (0.01%). Insiders that own company stock include Connie Matsui , Helen Torley , James M Daly , Jean-Pierre Bizzari , Jeffrey William Henderson , Matthew L Posard , Michael J Labarre and Nicole Labrosse . View institutional ownership trends .

How do I buy shares of Halozyme Therapeutics?

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Halozyme Therapeutics have any subsidiaries?

The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH. Read More

NASDAQ:HALO

Halozyme Therapeutics (HALO) Stock Price, News & Analysis

→ [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad)

Free HALO Stock Alerts

$38.04

+0.02 (+0.05%)

(As of 12:55 PM ET)

Compare

Today's Range: $37.86
▼
$38.41
50-Day Range: $34.64
▼
$41.95
52-Week Range: $29.85
▼
$45.00

Volume: 189,545 shs
Average Volume: 1.26 million shs
Market Capitalization: $4.83 billion

P/E Ratio: 18.03
Dividend Yield: N/A
Price Target: $53.29

Get Halozyme Therapeutics alerts:

Halozyme Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 38.9% Upside
$53.29 Price Target
Short Interest: Bearish
6.28% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.12
Upright™ Environmental Score
News Sentiment: 0.50
Based on 12 Articles This Week
Insider Trading: Selling Shares
$1.20 M Sold Last Quarter
Proj. Earnings Growth: 24.92%
From $3.33 to $4.16 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.89 out of 5 stars

Medical Sector

5th out of 914 stocks

Biological Products, Except Diagnostic Industry

2nd out of 153 stocks

3.4

Analyst's Opinion

Consensus Rating
Halozyme Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Halozyme Therapeutics has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
6.28% of the float of Halozyme Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Halozyme Therapeutics has a short interest ratio ("days to cover") of 6.1.
Change versus previous month
Short interest in Halozyme Therapeutics has recently decreased by 3.78%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Halozyme Therapeutics does not currently pay a dividend.
Dividend Growth
Halozyme Therapeutics does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Halozyme Therapeutics has received a 65.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Biopharmaceuticals" and "Medical technology engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for Halozyme Therapeutics is -1.12.

2.5

News and Social Media Coverage

News Sentiment
Halozyme Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Halozyme Therapeutics this week, compared to 5 articles on an average week.
Search Interest
17 people have searched for HALO on MarketBeat in the last 30 days. This is an increase of 55% compared to the previous 30 days.
MarketBeat Follows
Only 13 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,196,800.00 in company stock.
Percentage Held by Insiders
Only 2.40% of the stock of Halozyme Therapeutics is held by insiders.
Percentage Held by Institutions
97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

4.4

Earnings and Valuation

Earnings Growth
Earnings for Halozyme Therapeutics are expected to grow by 24.92% in the coming year, from $3.33 to $4.16 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Halozyme Therapeutics is 18.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.02.
Price to Earnings Ratio vs. Sector
The P/E ratio of Halozyme Therapeutics is 18.18, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 179.83.
Price to Earnings Growth Ratio
Halozyme Therapeutics has a PEG Ratio of 0.46. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Halozyme Therapeutics has a P/B Ratio of 60.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

About Halozyme Therapeutics Stock (NASDAQ:HALO)

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

HALO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HALO Stock News Headlines

April 18, 2024 | insidertrades.com

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre Sells 10,000 Shares

April 17, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Halozyme on OCREVUS SC Prospects and Enhanze Technology Potential

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

April 17, 2024 | americanbankingnews.com

Halozyme Therapeutics' (HALO) "Buy" Rating Reaffirmed at Benchmark

April 16, 2024 | markets.businessinsider.com

9 Analysts Have This To Say About Halozyme Therapeutics

April 13, 2024 | americanbankingnews.com

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Moderate Buy" by Brokerages

April 10, 2024 | seekingalpha.com

Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics

April 10, 2024 | nasdaq.com

Validea Detailed Fundamental Analysis - HALO

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

April 9, 2024 | stocknews.com

3 Biotech Stocks to Buy in 2024

April 8, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and MacroGenics (MGNX)

April 8, 2024 | americanbankingnews.com

Q3 2024 Earnings Forecast for Halozyme Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:HALO)

April 4, 2024 | finance.yahoo.com

Is Now The Time To Put Halozyme Therapeutics (NASDAQ:HALO) On Your Watchlist?

March 29, 2024 | finance.yahoo.com

Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?

March 29, 2024 | investorplace.com

The 3 Best Biotech Stocks to Buy in Q2 2024

March 27, 2024 | finance.yahoo.com

Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?

March 16, 2024 | finance.yahoo.com

HALO Apr 2024 35.000 put

March 13, 2024 | investorplace.com

7 Biotech Stocks to Buy as Sector Rotation Ramps Up

March 12, 2024 | finance.yahoo.com

I:RUT Mar 2024 Weekly 1905.000

March 8, 2024 | markets.businessinsider.com

TD Cowen Reaffirms Their Buy Rating on Halozyme (HALO)

March 1, 2024 | msn.com

TD Cowen Initiates Coverage of Halozyme Therapeutics (HALO) with Outperform Recommendation

February 29, 2024 | stocknews.com

3 Biotech Stocks for Sustainable Returns

February 29, 2024 | finance.yahoo.com

Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 20,000 Shares of Halozyme ...

February 27, 2024 | prnewswire.com

Halozyme to Participate in Upcoming Investor Conferences

February 23, 2024 | finance.yahoo.com

Analyst Estimates: Here's What Brokers Think Of Halozyme Therapeutics, Inc. (NASDAQ:HALO) After Its Full-Year Report

February 22, 2024 | finance.yahoo.com

Halozyme Therapeutics Full Year 2023 Earnings: EPS Beats Expectations

February 21, 2024 | money.usnews.com

Halozyme Therapeutics Inc.

See More Headlines

Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/20/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:HALO
CUSIP: 40637H10
CIK: 1159036
Web: www.halozyme.com
Phone: 858-794-8889
Fax: 858-704-8311
Employees: 373
Year Founded: 1998

Price Target and Rating

Average Stock Price Target: $53.29
High Stock Price Target: $72.00
Low Stock Price Target: $40.00
Potential Upside/Downside: +40.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.11
Trailing P/E Ratio: 18.02
Forward P/E Ratio: 11.42
P/E Growth: 0.46
Net Income: $281.59 million
Net Margins: 33.96%
Pretax Margin: 42.01%
Return on Equity: 248.20%
Return on Assets: 19.13%

Debt

Debt-to-Equity Ratio: 17.89
Current Ratio: 6.64
Quick Ratio: 5.50

Sales & Book Value

Annual Sales: $829.25 million
Price / Sales: 5.83
Cash Flow: $3.15 per share
Price / Cash Flow: 12.08
Book Value: $0.63 per share
Price / Book: 60.35

Miscellaneous

Outstanding Shares: 127,050,000
Free Float: 124,005,000
Market Cap: $4.83 billion
Optionable: Optionable
Beta: 1.25

Social Links

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Dr. Helen I. Torley M.B. Ch. B. (Age 61)
M.R.C.P., President, CEO & Director
Comp: $1.82M
Ms. Nicole LaBrosse (Age 41)
Senior VP & CFO
Comp: $849.36k
Dr. Michael J. LaBarre Ph.D. (Age 60)
Senior VP & Chief Technical Officer
Comp: $843.89k
Mr. Mark Snyder Esq.
Senior VP & Chief Legal Officer
Ms. Cortney Caudill M.B.A.
Chief Operations Officer
Ms. Tram Bui
Head of Investor Relations & Corporate Communications
Ms. Amy Marinne Fox
Chief Human Resources Officer
Dr. Steve Knowles MBBS
Chief Medical Officer
Dr. Christopher Bryant Ph.D. (Age 63)
Chief Manufacturing Officer & Head of Technical Operations
Ms. Kristin Schwartzbauer
Head of Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HALO Stock Analysis - Frequently Asked Questions

Should I buy or sell Halozyme Therapeutics stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HALO shares.
View HALO analyst ratings or view top-rated stocks.
What is Halozyme Therapeutics' stock price target for 2024?: 7 equities research analysts have issued 1 year price targets for Halozyme Therapeutics' stock. Their HALO share price targets range from $40.00 to $72.00. On average, they expect the company's stock price to reach $53.29 in the next twelve months. This suggests a possible upside of 38.9% from the stock's current price.
View analysts price targets for HALO or view top-rated stocks among Wall Street analysts.
How have HALO shares performed in 2024?: Halozyme Therapeutics' stock was trading at $36.96 at the beginning of 2024. Since then, HALO shares have increased by 3.8% and is now trading at $38.36.
View the best growth stocks for 2024 here.
When is Halozyme Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our HALO earnings forecast.
How were Halozyme Therapeutics' earnings last quarter?: Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued its earnings results on Tuesday, February, 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.77 by $0.02. The biopharmaceutical company earned $230.04 million during the quarter, compared to analysts' expectations of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a trailing twelve-month return on equity of 248.20%.
What ETFs hold Halozyme Therapeutics' stock?: ETFs with the largest weight of Halozyme Therapeutics (NASDAQ:HALO) stock in their portfolio include Future Fund Long/Short ETF (FFLS), Future Fund Active ETF (FFND), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), BlackRock Future Innovators ETF (BFTR), Goldman Sachs Future Health Care Equity ETF (GDOC), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What guidance has Halozyme Therapeutics issued on next quarter's earnings?: Halozyme Therapeutics updated its FY 2024 earnings guidance on Tuesday, February, 20th. The company provided EPS guidance of 3.550-3.900 for the period, compared to the consensus estimate of 3.510. The company issued revenue guidance of $915.0 million-$985.0 million, compared to the consensus revenue estimate of $961.1 million.
What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?: 12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.
What other stocks do shareholders of Halozyme Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).
Who are Halozyme Therapeutics' major shareholders?: Halozyme Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (0.32%), Hodges Capital Management Inc. (0.25%), Los Angeles Capital Management LLC (0.10%), Brookstone Capital Management (0.05%), FCF Advisors LLC (0.02%) and Park Avenue Securities LLC (0.01%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Matthew L Posard, Michael J Labarre and Nicole Labrosse.
View institutional ownership trends.
How do I buy shares of Halozyme Therapeutics?: Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Halozyme Therapeutics have any subsidiaries?: The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.
Read More

This page (NASDAQ:HALO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Halozyme Therapeutics (HALO) Stock Price, News & Analysis

Halozyme Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Halozyme Therapeutics Stock (NASDAQ:HALO)

HALO Stock Price History

HALO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

HALO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™